

EBV Increases Risk of Stomach Cancer; CBCD Reviews Medical Studies

"We have found evidence that Epstein-Barr virus (EBV) reactivation increases the risk to develop premalignant and malignant gastric lesions." (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, September 4, 2015 /EINPresswire.com/ --

"Infected with the EBV virus? We recommend taking <u>Gene-Eden-VIR</u> or <u>Novirin</u>." – Greg Bennett, CBCD

Most people associate the Epstein Barr Virus (EBV) with infectious mononucleosis (Mono, also known as "the kissing disease"). However, science



is showing that EBV is also linked to peptic ulcer disease (a peptic ulcer or stomach ulcer, is a break in the lining of the stomach, first part of the small intestine, or occasionally the lower esophagus) and these ulcers are considered a risk factor for gastric cancer. (1)



Gastric cancer (GC) is the second cause of death from cancer worldwide.

Dr. Martinez-Lopez

For example, Dr. Martinez-Lopez and colleagues wrote in the journal "Viruses" that their results "support a role for EBV in GC and early precursor lesions, either as directly oncogenic (causing cancer), infecting epithelial cells or indirectly as an inflammatory trigger." (2) Gastric cancer (GC) is the second cause of death from cancer worldwide. Dr. Martinez-Lopez and team are from the Virology and Cancer Research Unit at the Federico Gomez Children's Hospital of Mexico.

Click to learn more about **EBV** symptoms.

The Center for the Biology of Chronic Disease (CBCD) therefore recommends that individuals infected with EBV take Gene-Eden-VIR or Novirin. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Gene-Eden-VIR and Novirin formula is effective against HSV and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with EBV...reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (3) The study authors also wrote that, "We observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (3) In addition,

this natural antiviral was recently proven to reduce mental and physical fatigue in a post-marketing clinical study that followed FDA guidelines.

Both products can be ordered online on the Gene-Eden-VIR and Novirin websites, here:

http://www.gene-eden-vir.com

and

http://www.novirin.com

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Dr. Martinez-Lopez further wrote that "Epstein-Barr Virus (EBV) infection has been associated with several types of lymphoma and nasopharyngeal carcinoma (NPC). More than 80% of lymphoepithelioma-like (LEL) GCs, a rare GC histologically similar to NPC, and about 10% of other common types of GCs are also positive for EBV." (2) In other words, EBV is linked to many forms of stomach cancer.

EBV chronically infects about 95% of the adult population, with virus usually present in B cells in a latent stage. (2) However, not everyone infected will develop cancer. According to Dr. Polansky, and his book "Microcompetition with Foreign DNA and the Origin of Chronic Disease," people develop cancer when the number of latent viruses passes a certain threshold. One of the reasons for an increase in the number of latent viruses is a weak immune system.

The CBCD offers a free download of Dr. Polansky's book to those who are interested in reading it.

http://www.cbcd.net/Book.php

Dr. Fujiwara wrote that people with a chronic EBV infection face a poor outcome. In addition to constant symptoms of Mononucleosis, they can also develop "life-threatening complications including hemophagocytic lymphohisticocytosis (a condition that causes the immune system to attack the body's own tissues), organ failure, and malignant lymphomas (cancer)." (3) Dr. Fujiwara is from the Department of Infectious Diseases, National Research Institute for Child Health and Development in Tokyo, Japan.

What standard treatments are available for EBV infections?

"A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans." (3) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Gene-Eden-VIR and Novirin.

In light of the above information, the CBCD recommends that individuals infected with the Epstein Barr Virus (EBV) take Gene-Eden-VIR or Novirin.

References:

- (1) Cárdenas-Mondragón MG1, Torres J, Flores-Luna L, Carreón-Talavera R, Camorlinga-Ponce M, Fuentes-Pananá EM. "Epstein-Barr virus association with peptic ulcer disease." Anal Cell Pathol (Amst). 2015;2015:164840.
- (2) Juan L.E. Martínez-López 1,2email, Javier Torres 3email, Margarita Camorlinga-Ponce 3email, Alejandra Mantilla 4email, Yelda A. Leal 5email and Ezequiel M. Fuentes-Pananá 1Evidence of Epstein-Barr Virus Association with Gastric Cancer and Non-Atrophic Gastritis Viruses2014, 6(1), 301-318
- (3) Polansky H, Itzkovitz E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Pharmacology & Pharmacy, 2013, 4, 1-8 http://dx.doi.org/10.4236/pp.2013.46A001
- (4) Fujiwara S1, Kimura H, Imadome K, Arai A, Kodama E, Morio T, Shimizu N, Wakiguchi H. Current research on chronic active Epstein-Barr virus infection in Japan. Pediatr Int. 2014 Apr;56 (2):159-66.

Greg Bennett CBCD 585-250-9999 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.